Background-Immunotherapy with recombinant interleukin 2 (rIL 2) has been extensively used to treat cancer but its use has been hampered by serious side effects including severe hypotension, arrhythmias, and myocardial infarction. Objective-To assess the effects of rIL 2 on human left ventricular function.
(0.46) to 2-37 (0.43) EDV/s (p < 0.01). Left ventricular segmental hypokinesia developed in 6 patients. Myocardial enzyme concentrations remained normal throughout the study. Conclusions-The results of this study confirmed that rIL 2 produces important haemodynamic changes, predominantly related to decreased systemic resistance. However, the observed reduction in PFR in most patients suggested that rIL 2 might exert its action at the level of the heart muscle itself. The localised systolic dysfunction in some patients suggested that rIL 2 might also adversely affect myocardial perfusion. (Br Heart3' 1994; 71:166-169) Recombinant interleukin 2 (rIL 2) has been extensively used, both alone and in association with lymphokine-activated killer cells, to treat malignant neoplasms, such as renal cell carcinoma and melanoma.' rIL 2 commonly causes cardiovascular side effects. Almost all clinical trials of rIL 2 have reported important complications such as tachycardia and hypotension,34 fluid retention,5 myocardial infarction,67 myocarditis,5 complete heart block,9 and a decrease in ejection fraction.'0 Although the mechanisms responsible for the cardiovascular effects of rIL 2 are largely unknown, a recent study suggested a partial relation with a decrease in peripheral vascular resistance, resembling the early phase of septic shock." The cardiovascular collapse associated with septic shock is largely caused by bacterial endotoxin,"2 which is known to stimulate the synthesis and release of different cytokines and biological mediators with hypotensive activity including tumour necrosis factor (TNF). Hesse et al"3 and Beutler et aP4 proposed that TNF contributed to the cardiovascular collapse of septic shock by releasing secondary mediators such as endothelium-derived relaxing factor (EDRF), a hypotensive agent,'5 which accounts for the cardiovascular changes associated with endotoxin and cytokine administration.'6'7 There is experimental evidence that human monocytes stimulated with rIL 2 release a soluble factor that severely impairs myocardial function. '8 To determine whether the haemodynamic changes during rIL 2 therapy were also related to a cardiotoxic effect we studied ventricular function in 22 was significantly reduced during rIL 2 infusion in most of the 22 patients and often in the absence of a concomitant impairment of systolic function, suggesting a primary effect on the diastolic properties of the myocardium, possibly induced by transient interstitial oedema. Indeed, in all our patients body weight increased after rIL 2, probably because of fluid retention.5 An earlier study showed that myocardial oedema may cause compliance to decrease without affecting myocardial contractility. 27 The major determinants of the atrioventricular pressure difference during early diastole are the rate and duration of ventricular relaxation, passive ventricular compliance, the end systolic volume, the compliance of the atrium, and the atrial pressure at the onset of atrioventricular valve inflow.28 Therefore, among other factors, the modest but significant decrease in central venous pressure seen in our patients might also have contributed to a reduction in diastolic filling rate through a decrease in atrial filling pressure.
In six patients localised systolic wall motion was impaired immediately after rIL 2 administration. In all cases the hypokinesia affected the anteroseptal wall and was associated with reduction in peak emptying and filling rates and ejection fraction. Although these changes were associated with ST-T alterations in only two patients they resemble the pattern of left ventricular function impairment seen during ischaemia.29 30 This suggests the possibility that in some patients with latent coronary artery disease rIL-2 may reduce regional coronary flow and hence cause myocardial ischaemia and regional wall motion abnormalities. Clinical studies are needed to assess changes in myocardial perfusion after in vivo rIL 2 administration.
CLINICAL IMPLICATIONS
Treatment with rIL 2 always induced significant haemodynamic changes, including a decrease in arterial pressure and a compensatory increase in heart rate. In addition, some patients developed variable degrees of reversible left ventricular dysfunction. When careful attention is paid to fluid status and blood pressure support patients can be safely managed through the haemodynamic toxicity of this therapy. However, in patients with cancer and with known or suspected coronary disease, the possibility that rIL 2 cytokineinduced deterioration of their cardiac condition should be taken into account.
